108 results on '"Schlumbrecht M"'
Search Results
2. BIOMARKER PREDICTION OF OUTCOME VARIES BY RACE IN UTERINE SEROUS CARCINOMA: EP483
- Author
-
Bussies, P, George, S, Pinto, A, Huang, M, Slomovitz, B, and Schlumbrecht, M
- Published
- 2019
- Full Text
- View/download PDF
3. ASSOCIATIONS BETWEEN THROMBOCYTOSIS, PREDICTIVE BIOMARKERS, AND SURVIVAL OUTCOMES IN UTERINE SEROUS CARCINOMA: EP482
- Author
-
Bussies, P, George, S, Pinto, A, Huang, M, Slomovitz, B, and Schlumbrecht, M
- Published
- 2019
- Full Text
- View/download PDF
4. 240 First year experience of hereditary testing in gynecological cancer patients in a clinical setting in the bahamas
- Author
-
Bowe, S, Butler, R, Halliday, D, Geremias, R, Cerbon, D, Huang, M, Roberts, R, Schlumbrecht, M, Slomovitz, B, and George, S
- Published
- 2019
- Full Text
- View/download PDF
5. 48 Variations in endometrial cancer risk and histologic distribution by caribbean nativity
- Author
-
Schlumbrecht, M, George, S, Pinto, A, Huang, M, Slomovitz, B, and Koru-Sengul, T
- Published
- 2019
- Full Text
- View/download PDF
6. EP482 Associations between thrombocytosis, predictive biomarkers, and survival outcomes in uterine serous carcinoma
- Author
-
Bussies, P, primary, George, S, additional, Pinto, A, additional, Huang, M, additional, Slomovitz, B, additional, and Schlumbrecht, M, additional
- Published
- 2019
- Full Text
- View/download PDF
7. EP483 Biomarker prediction of outcome varies by race in uterine serous carcinoma
- Author
-
Bussies, P, primary, George, S, additional, Pinto, A, additional, Huang, M, additional, Slomovitz, B, additional, and Schlumbrecht, M, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Phase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
- Author
-
Miller, D., primary, Miller, D.S., additional, Cheung, E., additional, Huang, M., additional, Schlumbrecht, M., additional, Garcia, A., additional, Loch, M., additional, Jernigan, A., additional, Li, Z., additional, Chen, M., additional, and Chen, J., additional
- Published
- 2019
- Full Text
- View/download PDF
9. 240 First year experience of hereditary testing in gynecological cancer patients in a clinical setting in the bahamas
- Author
-
Bowe, S, primary, Butler, R, additional, Halliday, D, additional, Geremias, R, additional, Cerbon, D, additional, Huang, M, additional, Roberts, R, additional, Schlumbrecht, M, additional, Slomovitz, B, additional, and George, S, additional
- Published
- 2019
- Full Text
- View/download PDF
10. 48 Variations in endometrial cancer risk and histologic distribution by caribbean nativity
- Author
-
Schlumbrecht, M, primary, George, S, additional, Pinto, A, additional, Huang, M, additional, Slomovitz, B, additional, and Koru-Sengul, T, additional
- Published
- 2019
- Full Text
- View/download PDF
11. A comparison of molecular tumor profiles from hispanic and non-hispanic women with ovarian cancer
- Author
-
Hinshaw, H., primary, Huang, M., additional, George, S., additional, Pinto, A., additional, Pearson, J., additional, Slomovitz, B., additional, and Schlumbrecht, M., additional
- Published
- 2019
- Full Text
- View/download PDF
12. Disparities in the evolution of polypharmacy among women with ovarian cancer
- Author
-
Oldak, S., primary, Ioannou, S., additional, Kamath, P., additional, Huang, M., additional, Slomovitz, B., additional, and Schlumbrecht, M., additional
- Published
- 2019
- Full Text
- View/download PDF
13. Preparation in the Business and Practice of Medicine: Perspectives from Graduates and Fellowship Directors
- Author
-
Siemon, J., primary, Morales, G., additional, Huang, M., additional, Pearson, J.M., additional, Slomovitz, B., additional, and Schlumbrecht, M., additional
- Published
- 2017
- Full Text
- View/download PDF
14. 1033P - Phase Ib/IIa study assessing the safety and efficacy of adding AL3818 (anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
- Author
-
Miller, D., Miller, D.S., Cheung, E., Huang, M., Schlumbrecht, M., Garcia, A., Loch, M., Jernigan, A., Li, Z., Chen, M., and Chen, J.
- Published
- 2019
- Full Text
- View/download PDF
15. Ovarian cancer knowledge in Hispanic women: Bridging the gap
- Author
-
Schlumbrecht, M., primary, Dettler, J., additional, Yarian, R., additional, Niven, C., additional, Salmon, K., additional, and Singh, D., additional
- Published
- 2014
- Full Text
- View/download PDF
16. Abstract number 7: Potential prognostic value of perineural invasion in vulvar squamous cell carcinoma
- Author
-
Gehlot, A., primary, Schlumbrecht, M., additional, Holthoff, E., additional, Burnett, A., additional, Jeffus, S., additional, Quick, M., additional, Post, S., additional, and Stone, R., additional
- Published
- 2014
- Full Text
- View/download PDF
17. Sleep disturbances: A critical issue among gynecologic cancer survivors
- Author
-
Tung, C., primary, Westin, S., additional, Sun, C., additional, Lacour, R., additional, Meyer, L., additional, Schlumbrecht, M., additional, and Bodurka, D., additional
- Published
- 2013
- Full Text
- View/download PDF
18. Physician preferences for involvement in survivorship care: Are benign gynecologists ready?
- Author
-
Schlumbrecht, M., primary, Milbourne, A., additional, Sun, C., additional, Huang, M., additional, and Bodurka, D., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Molecular clustering based on ERΑ and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum
- Author
-
Schlumbrecht, M., primary, Xie, S., additional, Shipley, G., additional, Urbauer, D., additional, and Broaddus, R., additional
- Published
- 2012
- Full Text
- View/download PDF
20. Survivorship Care: Who Do Gynecologic Cancer Patients Prefer?
- Author
-
Schlumbrecht, M., primary, Sun, Charlotte C., additional, Huang, M., additional, Milbourne, A., additional, and Bodurka, D., additional
- Published
- 2012
- Full Text
- View/download PDF
21. Sweet Response: Hyperglycemia and Hypertriglyceridemia as Biomarkers of Clinical Benefit for Everolimus in Patients with Recurrent Endometrial Cancer
- Author
-
Stone, R., primary, Schlumbrecht, M., additional, Johnston, T., additional, Iglesias, D., additional, Lu, K., additional, Coleman, R., additional, and Soliman, P., additional
- Published
- 2012
- Full Text
- View/download PDF
22. Lifestyle modification in cervical cancer survivors: An ongoing need
- Author
-
Schlumbrecht, M., primary, Sun, C., additional, Westin, S., additional, Zandstra, F., additional, Tung, C., additional, Denton, K., additional, Rhodes, H., additional, Garcia, E., additional, Levenback, C., additional, and Bodurka, D., additional
- Published
- 2011
- Full Text
- View/download PDF
23. Importance of lifestyle modification in cervical cancer survivors.
- Author
-
Schlumbrecht, M. P., primary, Sun, C. C., additional, Westin, S. N., additional, Zandstra, F., additional, Denton, K., additional, Rhodes, H., additional, Gonzales, D. A., additional, Garcia, E. A., additional, Levenback, C., additional, and Bodurka, D. C., additional
- Published
- 2010
- Full Text
- View/download PDF
24. Prognostic significance of obesity in high-grade serous carcinoma of the ovary
- Author
-
Schlumbrecht, M., primary, Urbauer, D., additional, Gershenson, D., additional, and Broaddus, R., additional
- Published
- 2009
- Full Text
- View/download PDF
25. Multi-institutional retrospective analysis of lymphadenectomy in early stage adenocarcinoma of the cervix
- Author
-
SCHLUMBRECHT, M, primary, KNOWLES, L, additional, MILLER, D, additional, and SCHORGE, J, additional
- Published
- 2007
- Full Text
- View/download PDF
26. Abstract number 7: Potential prognostic value of perineural invasion in vulvar squamous cell carcinoma
- Author
-
Schlumbrecht, M., Holthoff, E., Burnett, A., Jeffus, S., Quick, M., Post, S., and Stone, R.
- Published
- 2014
- Full Text
- View/download PDF
27. Sleep disturbances: A critical issue among gynecologic cancer survivors
- Author
-
Westin, S., Sun, C., Lacour, R., Meyer, L., Schlumbrecht, M., and Bodurka, D.
- Published
- 2013
- Full Text
- View/download PDF
28. Pyometra after thermal endometrial ablation.
- Author
-
Schlumbrecht M, Balgobin S, and Word L
- Published
- 2007
- Full Text
- View/download PDF
29. Incident Invasive Breast Cancer, Geographic Location of Residence, and Reported Average Time Spent Outside.
- Author
-
Schlumbrecht, M. P. and Chang, S.
- Subjects
BREAST cancer ,DISEASE incidence ,CANCER risk factors ,HOMESITES ,PHYSIOLOGICAL effects of solar radiation ,VITAMIN D - Abstract
The article focuses on research on the association of breast cancer incidence with the geographic location of residence and average time spent outdoors. It references the study "Incident Invasive Breast Cancer, Geographic Location of Residence and Reported Average Time Spent Outside," by A. E. Miller and colleagues, published in a 2009 issue of "Cancer Epidemiology Biomarkers and Prevention." It is said that geographic location does not affect risk of breast cancer. It adds that vitamin D exposure can offer protection against breast cancer.
- Published
- 2010
30. Living Well: Protocol for a web-based program to improve quality of life in rural and urban ovarian cancer survivors.
- Author
-
Pennington KP, Schlumbrecht M, McGregor BA, Goodheart MJ, Heron L, Zimmerman B, Telles R, Zia S, Penedo FJ, and Lutgendorf SK
- Subjects
- Female, Humans, Middle Aged, Adaptation, Psychological, Anxiety therapy, Anxiety psychology, Healthy Lifestyle, Mindfulness methods, Stress, Psychological therapy, Stress, Psychological psychology, Urban Population, Randomized Controlled Trials as Topic, Multicenter Studies as Topic, Clinical Trials, Phase II as Topic, Cancer Survivors psychology, Depression therapy, Depression epidemiology, Depression psychology, Fatigue therapy, Fatigue psychology, Internet-Based Intervention, Ovarian Neoplasms psychology, Ovarian Neoplasms therapy, Quality of Life, Rural Population
- Abstract
Background: Ovarian cancer (OC) survivors commonly experience chronic symptoms including anxiety, depression, sleep disturbances, fatigue, physical symptoms, poor health-related quality of life (HRQOL), and a generally poor prognosis. Additionally, factors such as social isolation, stress, and depression are associated with key biological processes promoting tumor progression and poorer survival. Accessible psychosocial interventions to improve HRQOL and clinical outcomes are needed. This need is particularly true in rural settings where survivors may have less access to clinic-based support systems., Methods: The Living Well Study, a cluster-randomized Phase II multi-site clinical trial, is designed to evaluate the efficacy of a group-based, web-delivered psychosocial intervention (Mindful Living) verses a Health Promotion active control (Healthy Lifestyles) in increasing HRQOL and decreasing perceived stress (primary outcomes), depressive mood, anxiety, and fatigue (secondary outcomes) for 256 OC survivors who are <5 years post-primary therapy. Mindful Living targets key concerns of OC survivors and teaches stress reduction skills and coping strategies utilizing cognitive behavioral, mindfulness, and acceptance and commitment therapies. Healthy Lifestyles provides lifestyle information including exercise, nutrition, sleep, and other survivorship topics. Interventions consist of 11 consecutive weekly group sessions lasting 1.5-2 h led by trained facilitators and two booster sessions. Participants complete psychosocial questionnaires at baseline, post-intervention, at 6-months, and at 12-months. A subset completes bloodspots for analysis of inflammatory biology., Conclusion: Easily accessible psychosocial interventions addressing key concerns of OC survivors are an unmet need. The Mindful Living intervention has the potential to substantially enhance HRQOL and decrease distress in OC survivors. Trial registrationclinicaltrials.gov Identifier: NCT04533763., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Exercise and nutrition to improve cancer Treatment-Related outcomes (ENICTO).
- Author
-
Schmitz KH, Brown JC, Irwin ML, Robien K, Scott JM, Berger NA, Caan B, Cercek A, Crane TE, Evans SR, Ligibel JA, Meyerhardt JA, Agurs-Collins T, Basen-Engquist K, Bea JW, Cai SF, Cartmel B, Chinchilli VM, Demark-Wahnefried W, Dieli-Conwright CM, DiPietro L, Doerksen SE, Edelstein SL, Elena J, Evans W, Ferrucci LM, Foldi J, Freylersythe S, Furberg H, Jones LW, Levine R, Moskowitz CS, Owusu C, Penedo F, Rabin BA, Ratner E, Rosenzweig M, Salz T, Sanft T, Schlumbrecht M, Spielmann G, Thomson CA, Tjaden AH, Weiser MR, Yang S, Yu AF, and Perna FM
- Abstract
Chemotherapy treatment-related side-effects are common and increase the risk of suboptimal outcomes. Exercise interventions during cancer treatment improve self-reported physical functioning, fatigue, anxiety, and depression, but it is unclear whether these interventions improve important clinical outcomes, such as chemotherapy relative dose intensity (RDI). The National Cancer Institute funded the Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO) Consortium, to address this knowledge gap. This paper describes the mechanisms hypothesized to underpin intervention effects on clinically-relevant treatment outcomes, briefly outlines each project's distinct research aims, summarizes the scope and organizational structure of ENICTO, and provides an overview of the integrated common data elements used to pursue research questions collectively. In addition, the paper includes a description of consortium-wide activities and broader research community opportunities for collaborative research. Findings from the ENICTO Consortium have the potential to accelerate a paradigm shift in oncology care such that cancer patients could receive exercise and nutrition programming as the standard of care in tandem with chemotherapy to improve RDI for a curative outcome., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
32. Comparison of antigenicity between frozen section vs non-frozen section tissue blocks: An immunohistochemical study of antibodies commonly used in gynecologic pathology.
- Author
-
Obaid Q, Nadji M, Schlumbrecht M, and Pinto A
- Abstract
Objectives: Frozen section (FS) is a technique widely used intraoperatively to render a preliminary histopathologic diagnosis, allowing for immediate decisions at the time of surgery. We aimed to investigate potential variations in tissue antigenicity induced by rapid freezing in a variety of gynecologic tumor samples., Methods: A total of 177 FS and 177 non-frozen section (NFS) tissue slides were tested using a panel of immunostains commonly used in gynecologic pathology, including hormone receptors (estrogen receptor, progesterone receptor), HER2, mismatch repair proteins (MSH6, PMS2), programmed cell death 1 ligand 1 (PD-L1), p53, napsin A, and ɑ-methylacyl coenzyme-A racemase. Immunohistochemistry results were categorized as positive or negative, and positive cases were subsequently scored based on the distribution and intensity of the staining. Certain immunostains, such as HER2, PD-L1, and p53, were scored according to the established guidelines., Results: The overall concordance between FS and NFS blocks was 87%; among the 13% of discrepant cases, most (10.7%) were classified as minor, with only quantitative differences without foreseeable clinical significance. In 2.3% of cases, there were major qualitative changes with potential impact on disease management., Conclusions: We concluded that FS tissue blocks may, in most cases, safely be used for immunohistochemical studies because most discrepant cases showed only minor differences in staining, with no anticipated clinical significance. Nevertheless, for certain markers, including HER2, p53, and PMS2, a NFS block is preferred when that option is available., (© The Author(s) 2024. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
33. Emerging cancer disease burden in a rural sub-Saharan African population: northeast Nigeria in focus.
- Author
-
Ezenkwa US, Lawan AI, Garbati MA, Suleiman DE, Katagum DA, Kabir A, Adamu AI, Modu AK, Olanrewaju OD, Dachi RA, Abdullahi YM, Alkali M, Bojude DA, Usman HA, Omotoso A, Schlumbrecht M, George SHL, and Audu BM
- Abstract
Introduction: Sub-Saharan Africa (SSA) is plagued by myriads of diseases, mostly infectious; but cancer disease burden is rising among non-communicable diseases. Nigeria has a high burden of cancer, however its remote underserved culturally-conserved populations have been understudied, a gap this study sought to fill., Methods: This was a cross-sectional multi-institutional descriptive study of histologically diagnosed cancers over a four-year period (January 2019-December 2022) archived in the Departments of Pathology and Cancer Registries of six tertiary hospitals in the northeast of Nigeria. Data obtained included age at diagnosis, gender, tumor site and available cancer care infrastructure. Population data of the study region and its demographics was obtained from the National Population Commission and used to calculate incident rates for the population studied., Results: A total of 4,681 incident cancer cases from 2,770 females and 1,911 males were identified. The median age at diagnosis for females was 45 years (range 1-95yrs), and 56 years (range 1-99yrs) for males. Observed age-specific incidence rates (ASR) increased steadily for both genders reaching peaks in the age group 80 years and above with the highest ASR seen among males (321/100,000 persons) compared to females (215.5/100,000 persons). Breast, cervical, prostatic, colorectal and skin cancers were the five most common incident cancers. In females, breast, cervical, skin, ovarian and colorectal cancers were the top five malignancies; while prostate, haematolymphoid, skin, colorectal and urinary bladder cancers predominated in men., Conclusion: Remote SSA communities are witnessing rising cancer disease burden. Proactive control programs inclusive of advocacy, vaccination, screening, and improved diagnostics are needed., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2024 Ezenkwa, Lawan, Garbati, Suleiman, Katagum, Kabir, Adamu, Modu, Olanrewaju, Dachi, Abdullahi, Alkali, Bojude, Usman, Omotoso, Schlumbrecht, George and Audu.)
- Published
- 2024
- Full Text
- View/download PDF
34. Cervical cancer awareness, perception, and attitude among tertiary health institution students in northeastern Nigeria.
- Author
-
Muhammad ZB, Ezenkwa US, Imoudu IA, Katagum DA, Usman I, George SHL, Schlumbrecht M, and Audu BM
- Abstract
Background: The devastating scourge of cervical cancer in Africa is largely due to the absence of preventive interventions, driven by low awareness and poor perception of the disease in the continent. This work is a preliminary effort toward understanding key social drivers promoting this disease in our immediate environment with a view to mitigating it., Method: Female students of two tertiary health institutions in Azare, northeastern Nigeria, were approached to participate in this cross-sectional descriptive study. A structured self-administered questionnaire was administered to consenting participants and covered questions on their socio-demographics, awareness, perception, and attitude about/toward cervical cancer and its prevention. The responses were scrutinized for coherency and categorized into themes using summary statistics, while a chi-square test was used to determine the association between awareness of cervical cancer and participant age, marital status, religion, screening uptake, and willingness to undergo screen., Results: Awareness of cervical cancer was recorded among 174/230 (75.7%) respondents who enrolled in this study; 117 (67.2%) knew that it was preventable, but only three (1.3%) respondents had undergone screening. Among the aware participants, 91 (52.3%) and 131 (75.3%) knew that sexual intercourse and multiple sexual partners are risk factors for the disease, respectively. In contrast, knowledge of the etiology was poor; 82 (47.1%) respondents who knew it was preventable had heard about human papillomavirus (HPV), while 72 (41.4%) knew that HPV causes cervical cancer. Most (78%) of the participants expressed willingness to take a human papillomavirus vaccine or undergo screening (84.6%) if made available to them. Awareness was significantly associated with participants' age (p = 0.022) and willingness to undergo screening (p = 0.016)., Conclusion: This study revealed discordance between awareness and knowledge about cervical cancer. Educational initiatives reflective of population perception/knowledge of cervical cancer are needed to mitigate the rising incidence of this disease, especially among female healthcare providers., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Muhammad, Ezenkwa, Imoudu, Katagum, Usman, George, Schlumbrecht and Audu.)
- Published
- 2024
- Full Text
- View/download PDF
35. Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy.
- Author
-
Russell DH, Epstein JI, Kryvenko ON, Schlumbrecht M, Jorda M, and Pinto A
- Subjects
- Humans, Female, Middle Aged, Aged, Diagnosis, Differential, Retrospective Studies, Adenocarcinoma diagnosis, Adenocarcinoma pathology, Adenocarcinoma metabolism, Immunohistochemistry, Aged, 80 and over, Genital Neoplasms, Female pathology, Genital Neoplasms, Female diagnosis, Genital Neoplasms, Female metabolism, Carcinoma, Endometrioid pathology, Carcinoma, Endometrioid diagnosis, Carcinoma, Endometrioid metabolism, Endometrial Neoplasms pathology, Endometrial Neoplasms diagnosis, Endometrial Neoplasms metabolism, PAX8 Transcription Factor metabolism, PAX8 Transcription Factor analysis, GATA3 Transcription Factor metabolism, GATA3 Transcription Factor analysis, Adult, Keratin-7 metabolism, Receptors, Estrogen metabolism, Urinary Bladder pathology, Urinary Bladder metabolism, Urothelium pathology, Urothelium metabolism, Ovarian Neoplasms pathology, Ovarian Neoplasms diagnosis, Ovarian Neoplasms metabolism, Receptors, Progesterone metabolism, Carcinoma, Adenosquamous pathology, Carcinoma, Adenosquamous diagnosis, Carcinoma, Adenosquamous metabolism, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms metabolism, Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism
- Abstract
Context.—: There is limited literature describing gynecologic adenocarcinomas involving the urinary bladder and potential diagnostic pitfalls., Objective.—: To describe key features distinguishing metastatic (or extension of) gynecologic adenocarcinomas from urothelial carcinomas with glandular differentiation., Design.—: Retrospective review of surgical pathology cases of gynecologic adenocarcinomas involving the bladder from 2 different institutions, retrieved from surgical pathology archives, was performed. Morphologic features were recorded, along with immunohistochemistry results when available. Electronic medical records were reviewed for clinical and radiographic information., Results.—: Sixteen cases of gynecologic adenocarcinomas (9 endometrial endometrioid adenocarcinomas, 4 endometrial serous carcinomas, 2 high-grade tubo-ovarian serous carcinomas, and 1 cervical adenosquamous carcinoma) involving the bladder were identified. All included cases had mucosal involvement potentially mimicking primary bladder neoplasms, including 4 cases originally diagnosed as urinary carcinomas. Tumors expressed keratin 7 (12 of 13; 92%), PAX8 (11 of 12; 92%), estrogen receptor (11 of 15; 73%), p16 (8 of 11; 73%), progesterone receptor (8 of 14; 57%), GATA3 (5 of 12; 42%), and p63 (3 of 11; 27%); all tumors were negative for keratin 20 (0 of 12). Features supportive of Müllerian origin included prior history of gynecologic malignancy, lack of morphologic heterogeneity in nonendometrioid tumors, and immunophenotypic coexpression of PAX8 and estrogen receptor with absent GATA3. Potential pitfalls seen in a subset of cases included misleading radiologic and cystoscopic findings, replacement of the overlying urothelial mucosa by tumor mimicking precursor lesions, focal GATA3 and/or p63 positivity, and areas of squamous differentiation in tumors of endometrioid histology., Conclusions.—: A combination of clinical history, certain morphologic features, and proper selection of immunohistochemical stains is key for the correct diagnosis of secondary gynecologic adenocarcinomas involving the urinary bladder., Competing Interests: The authors have no relevant financial interest in the products or companies described in this article., (© 2024 College of American Pathologists.)
- Published
- 2024
- Full Text
- View/download PDF
36. Normal Risk Ovarian Screening Study: 21-Year Update.
- Author
-
Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, and Bast RC Jr
- Subjects
- Humans, Female, Predictive Value of Tests, Mass Screening, Ultrasonography, CA-125 Antigen, Ovarian Neoplasms diagnostic imaging, Endometrial Neoplasms
- Abstract
Purpose: The Normal Risk Ovarian Screening Study (NROSS) tested a two-stage screening strategy in postmenopausal women at conventional hereditary risk where significantly rising cancer antigen (CA)-125 prompted transvaginal sonography (TVS) and abnormal TVS prompted surgery to detect ovarian cancer., Methods: A total of 7,856 healthy postmenopausal women were screened annually for a total of 50,596 woman-years in a single-arm study (ClinicalTrials.gov identifier: NCT00539162). Serum CA125 was analyzed with the Risk of Ovarian Cancer Algorithm (ROCA) each year. If risk was unchanged and <1:2,000, women returned in a year. If risk increased above 1:500, TVS was undertaken immediately, and if risk was intermediate, CA125 was repeated in 3 months with a further increase in risk above 1:500 prompting referral for TVS. An average of 2% of participants were referred to TVS annually., Results: Thirty-four patients were referred for operations detecting 15 ovarian cancers and two borderline tumors with 12 in early stage (I-II). In addition, seven endometrial cancers were detected with six in stage I. As four ovarian cancers and two borderline tumors were diagnosed with a normal ROCA, the sensitivity for detecting ovarian and borderline cancer was 74% (17 of 23), and 70% of ROCA-detected cases (12 of 17) were in stage I-II. NROSS screening reduced late-stage (III-IV) disease by 34% compared with UKCTOCS controls and by 30% compared with US SEER values. The positive predictive value (PPV) was 50% (17 of 34) for detecting ovarian cancer and 74% (25 of 34) for any cancer, far exceeding the minimum acceptable study end point of 10% PPV., Conclusion: While the NROSS trial was not powered to detect reduced mortality, the high specificity, PPV, and marked stage shift support further development of this strategy.
- Published
- 2024
- Full Text
- View/download PDF
37. The Genetic Paradigm of Hereditary Breast and Ovarian Cancer (HBOC) in the Afro-Caribbean Population.
- Author
-
Cerbon D, Taylor D, Barreto-Coelho P, Rodriguez E, Schlumbrecht M, Hurley J, and George SHL
- Subjects
- Female, Humans, Black People genetics, Breast Neoplasms genetics, Breast Neoplasms epidemiology, Genetic Testing, Germ-Line Mutation, Hereditary Breast and Ovarian Cancer Syndrome genetics, Hereditary Breast and Ovarian Cancer Syndrome epidemiology, Ovarian Neoplasms genetics, Ovarian Neoplasms epidemiology, United States, Black or African American, Genetic Predisposition to Disease
- Abstract
Differences in tumor biology and genetic predisposition have been suggested as factors influencing overall survival and increased mortality in Black breast and ovarian cancer patients. Therefore, it is key to evaluate genetic susceptibilities in Afro-Caribbean patients because the black population in the US is not homogeneous. Identifying a high incidence of hereditary breast and ovarian cancer (HBOC) in Afro-Caribbean countries can lead to understanding the pattern of inherited traits in US-Caribbean immigrants and their subsequent generations. The paucity of projects studying the genetic landscape in these populations makes it difficult to design studies aimed at optimizing screening and prophylaxis strategies, which in turn, improve survival and mortality rates. This scoping review identifies and categorizes current research on the genetic paradigm of HBOC in the Afro-Caribbean population. We performed an evaluation of the evidence and generated a summary of findings according to preferred reporting items for systematic review and meta-analysis (PRISMA) Extension for Scoping Reviews guidelines. We included articles that assessed the incidence and prevalence of pathologic germline mutations and experience/barriers for genetic testing in Afro-Caribbean Countries and US-Caribbean patients. Our results highlight countries where genetic landscapes remain severely understudied and support recommending multigene testing in Caribbean-born patients. They highlight a need for further research on the genetic paradigm of HBOC in the Afro-Caribbean population to improve genetic testing/counseling and the subsequent adoption of early detection and risk reduction strategies.
- Published
- 2024
- Full Text
- View/download PDF
38. Point-of-Care Molecular Test for the Detection of 14 High-Risk Genotypes of Human Papillomavirus in a Single Tube.
- Author
-
Seely S, Zingg JM, Joshi P, Slomovitz B, Schlumbrecht M, Kobetz E, Deo S, and Daunert S
- Subjects
- Humans, Point-of-Care Systems, Point-of-Care Testing, Genotype, Human Papillomavirus Viruses, Papillomavirus Infections diagnosis
- Abstract
Cervical cancers constitute a large disease burden in developing countries, with the human papillomavirus (HPV) being responsible for most cervical lesions. Many regions in low-resource countries lack adequate access to sensitive point-of-care (POC) screening tools, preventing timely diagnosis and treatment. To reduce screening barriers, we developed a POC HPV molecular test that detects 14 high-risk HPV types in 30 min in a single assay. We introduced innovations to the underlying amplification (recombinase polymerase amplification) and detection methodologies such as improved probe design, reagent lyophilization, and pipette-less processing to increase sensitivity while enabling minimally trained personnel to conduct reproducible testing. Based on 198 clinically derived samples, we demonstrated a sensitivity of 93% and a specificity of 73% compared to an FDA-approved polymerase chain reaction-based clinical method. Our modified pipette-less simplified assay had a sensitivity of 96% and a specificity of 83%. The application of our assay is intended as a near-patient screening tool with further evaluation by a clinician for confirmation.
- Published
- 2023
- Full Text
- View/download PDF
39. Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory Oncology.
- Author
-
Penedo FJ, Natori A, Fleszar-Pavlovic SE, Sookdeo VD, MacIntyre J, Medina H, Moreno PI, Crane TE, Moskowitz C, Calfa CL, and Schlumbrecht M
- Subjects
- Humans, Female, Middle Aged, Cohort Studies, Retrospective Studies, Cross-Sectional Studies, Quality of Life, Minority Groups, Hospitalization, Emergency Service, Hospital, Ethnicity, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Importance: Patients with cancer experience multiple supportive care needs (eg, coping and financial counseling) that, if not addressed, may result in poor clinical outcomes. Limited work has assessed the factors associated with unmet needs in large and diverse samples of ambulatory oncology patients., Objective: To characterize the factors associated with unmet supportive care needs among ambulatory oncology patients and to assess whether such needs were associated with emergency department (ED) visits and hospitalizations., Design, Setting, and Participants: Between October 1, 2019, and June 30, 2022, cross-sectional retrospective analyses were performed in a large and diverse ambulatory cancer population via My Wellness Check, an electronic health record (EHR)-based supportive care needs and patient-reported outcomes (PROs) screening and referral program., Main Outcomes and Measures: Demographic characteristics, clinical characteristics, and clinical outcomes were extracted from EHRs. Data on PROs (ie, anxiety, depression, fatigue, pain, and physical function), health-related quality of life (HRQOL), and supportive care needs were also collected. Logistic regressions examined factors associated with unmet needs. Cumulative incidence of ED visits and hospitalizations were assessed by Cox proportional hazards regression models adjusting for covariates., Results: The 5236 patients in the study had a mean (SD) age of 62.6 (13.1) years and included 2949 women (56.3%), 2506 Hispanic or Latino patients (47.9%), and 4618 White patients (88.2%); 1370 patients (26.2%) indicated Spanish as their preferred language, according to their EHR. A total of 940 patients (18.0%) reported 1 or more unmet needs. Black race (adjusted odds ratio [AOR], 1.97 [95% CI, 1.49-2.60]), Hispanic ethnicity (AOR, 1.31 [95% CI, 1.10-1.55]), 1 to 5 years after diagnosis (AOR, 0.64 [95% CI, 0.54-0.77]), more than 5 years after diagnosis (AOR, 0.60 [95% CI, 0.48-0.76]), anxiety (AOR, 2.25 [95% CI, 1.71-2.95]), depression (AOR, 2.07 [95% CI, 1.58-2.70]), poor physical function (AOR, 1.38 [95% CI, 1.07-1.79]), and low HRQOL scores (AOR, 1.89 [95% CI, 1.50-2.39]) were associated with greater unmet needs. Patients with unmet needs had a significantly higher risk of ED visits (adjusted hazard ratio [AHR], 1.45 [95% CI, 1.20-1.74]) and hospitalizations (AHR, 1.36 [95% CI, 1.13-1.63]) relative to patients without unmet needs., Conclusions and Relevance: In this cohort study of ambulatory oncology patients, unmet supportive care needs were associated with worse clinical outcomes. Patients from racial and ethnic minority groups and those with greater emotional or physical burden were more likely to have 1 or more unmet needs. Results suggest that addressing unmet supportive care needs may be crucial for improving clinical outcomes, and targeted efforts should focus on specific populations.
- Published
- 2023
- Full Text
- View/download PDF
40. Surgically Treated Brain Metastases from Uterine Origin: A Case Series and Systematic Review.
- Author
-
Eatz T, Levy A, Merenzon M, Bystrom L, Berry K, Morell A, Bhatia S, Daggubati L, Higgins D, Schlumbrecht M, Komotar RJ, Shah AH, and Ivan ME
- Subjects
- Female, Humans, Middle Aged, Retrospective Studies, Survival Analysis, Treatment Outcome, Brain Neoplasms secondary, Brain Neoplasms surgery, Brain Neoplasms therapy, Radiosurgery methods, Uterine Neoplasms
- Abstract
Objective: We aimed to describe our institutional case series of 9 surgically treated uterine brain metastases and perform a survival analysis through a systematic review and a pooled individual patient data study., Methods: This study was divided into 2 sections: 1) a retrospective, single center patient series assessing outcomes of neurosurgical treatment modalities in patients with malignancy arising in the uterus with brain metastases and 2) a systematic review of the literature between 1980 and 2021 regarding treatment outcomes of individual patients with intracranial metastasis of uterine origin. Pooled cohort survival analysis was done via univariate and Cox regression multivariable analysis and Kaplan-Meier curves., Results: Final statistical analysis included a total of 124 pooled cohort patients: one hundred fifteen patients from literature review studies plus 9 patients from our institution. Median age at the time of diagnosis was 54 years. Median time from diagnosis of the primary cancer to brain metastasis was 19 months (0-166 months). Surgery and radiotherapy resulted in the highest median OS of 11 months (P < 0.001). Multivariable analyses indicated that the presence of more than one central nervous systemlesion had an increased risk on OS (P = 0.003). Microsurgery, stereotactic radiosurgery, and whole brain radiotherapy remain the evidence-based mainstay applicable to the treatment of multiple brain metastases., Conclusions: Brain metastases of cancer arising in the uterus appear to result most often in multiple lesions with dismal prognosis. The seemingly most efficacious treatment modality is surgery and radiotherapy. However, this treatment is often not an option when more than 1 or 2 brain lesions are present., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects.
- Author
-
Khan F, Rojas K, Schlumbrecht M, and Jeudin P
- Subjects
- Humans, Female, Receptors, Estrogen, Antineoplastic Agents, Hormonal therapeutic use, Quality of Life, Ovariectomy, Breast Neoplasms drug therapy
- Abstract
Approximately 80% of breast cancers are estrogen receptor-positive (ER+), and 68-80% of those occur in premenopausal or perimenopausal women. Since the introduction of tamoxifen for adjuvant endocrine therapy in women with non-metastatic ER+ breast cancer, subsequent trials have demonstrated an oncologic benefit with the addition of ovarian function suppression (OFS) to adjuvant endocrine therapy. Subsequently, therapies to either suppress or ablate ovarian function may be included in the treatment plan for patients that remain premenopausal or perimenopausal after upfront or adjuvant chemotherapy and primary surgery. One strategy for OFS, bilateral salpingo-oophorectomy (BSO), has lasting implications, and the routine recommendation for this strategy warrants a critical analysis in this population. The following is a narrative review of the utility of ovarian suppression or ablation (through either bilateral oophorectomy or radiation) in the context of adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). The long-term sequelae of bilateral oophorectomy include cardiovascular and bone density morbidity along with sexual dysfunction, negatively impacting overall quality of life. As gynecologists are the providers consulted to perform bilateral oophorectomies in this population, careful consideration of each patient's oncologic prognosis, cardiovascular risk, and psychosocial factors should be included in the preoperative assessment to assist in shared decision-making and prevent the lifelong adverse effects that may result from overtreatment.
- Published
- 2023
- Full Text
- View/download PDF
42. Symptoms and Needs Monitoring in Diverse Ambulatory Oncology Patients: Usage Characteristics and Impact on Emergency Room Visits and Hospitalization.
- Author
-
Natori A, Sookdeo VD, Koru-Sengul T, Schlumbrecht M, Calfa CL, Maclntyre J, Benzo RM, Moreno PI, Crane TE, Garcia SF, and Penedo FJ
- Subjects
- Humans, Male, Aged, Retrospective Studies, Hospitalization, Emergency Service, Hospital, Ethnicity, Neoplasms therapy
- Abstract
Purpose: Symptoms and needs monitoring using patient-reported outcomes (PRO) is associated with improved clinical outcomes in cancer care. However, these improvements have been observed predominantly in non-Hispanic White patients using English assessments with high completion rates. The documented impact of such monitoring on system-level outcomes including emergency room (ER) visits and hospitalizations remains limited. We explored factors affecting the completion of PRO measures and evaluated clinical outcomes in an ambulatory oncology setting with a diverse racial, ethnic, and linguistic population., Methods: A retrospective analysis (October 2019-February 2022) was performed for patients with cancer assigned to My Wellness Check (MWC), a patient-portal-administered and electronic health record-based PRO assessment that generates automated alerts to oncology providers. Patient demographics, clinical characteristics, and clinical outcomes were collected. Logistic regression models examined factors affecting the completion of MWC questionnaires. Cumulative incidence of ER visits and hospitalization were assessed by Cox proportional hazards regression models adjusting for demographics., Results: We identified 9,553 patients; 43.1% (n = 4,117) answered one or more questions. Patients age 65 years or older (adjusted odds ratio [aOR], 0.77; P < .0001), male (aOR, 0.81; P < .0001), Hispanic/Latino ethnicity (aOR, 0.70; P < .0001), living without partners (aOR, 0.75; P < .0001), or receiving no treatment (aOR, 0.76; P < .0001) were less likely to answer MWC questionnaires. Patients who completed the entire MWC questionnaires had a reduced risk of an ER visit (adjusted hazard ratio, 0.78; P < .0001) and hospitalization (adjusted hazard ratio, 0.80; P = .0007) relative to patients who did not., Conclusion: Completing electronic health record-based PRO assessments was associated with significantly better clinical outcomes in a diverse cancer population. Specific patient groups were less likely to participate. Further research is needed to identify barriers to completing PRO measures and the long-term benefits of such programs.
- Published
- 2023
- Full Text
- View/download PDF
43. African ancestry is associated with aggressive endometrial cancer.
- Author
-
Sanchez-Covarrubias AP, Tabuyo-Martin AD, George S, and Schlumbrecht M
- Subjects
- Female, Humans, Endometrium, African People, Black People, Endometrial Neoplasms genetics
- Published
- 2023
- Full Text
- View/download PDF
44. Unique Considerations in Early Detection, Risk, and Awareness of Endometrial Cancer in Black Women.
- Author
-
Schlumbrecht M, Wright K, and George S
- Subjects
- Female, Humans, Early Detection of Cancer, United States epidemiology, Black or African American, Endometrial Neoplasms diagnosis, Endometrial Neoplasms epidemiology
- Abstract
Endometrial cancer is the most common gynecologic cancer in the United States. Over the last several decades, the incidence of aggressive tumors, and thus the rate of death from disease, has increased significantly. The population most affected by these epidemiologic shifts are Black women. Symptom awareness, lack of treatment access, and failure of providers to provide guideline-concordant care are just some of the drivers behind these changes. Race as a social construct has historically categorized women into groups that are not reflective of the nuanced personalization that is required for cancer prevention strategies and targeted cancer treatments. There is, however, an increasing understanding that disaggregation by place of birth and social context are important to understand care-seeking behaviors, genetic drivers of disease, and factors that lead to deleterious outcomes. In this review, we will focus on specific individual-level influences that impact disease diagnosis and care-seeking among Black women, recognizing that the global disparities which exist in this disease encompass multiple domains. Such considerations are crucial to understanding drivers of self-efficacy and to develop programs for knowledge awareness and empowerment within a framework that is both useful and acceptable to these diverse communities at risk.
- Published
- 2023
- Full Text
- View/download PDF
45. Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2 .
- Author
-
Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, and George S
- Subjects
- BRCA1 Protein genetics, BRCA2 Protein genetics, Carcinoma, Ovarian Epithelial, Fallopian Tubes, Female, Humans, Mutation genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology
- Abstract
Besides BRCA1 and BRCA2 , several other inheritable mutations have been identified that increase ovarian cancer risk. Surgical excision of the fallopian tubes and ovaries reduces ovarian cancer risk, but for some non- BRCA hereditary ovarian cancer mutations the benefit of this intervention is unclear. The fallopian tubes of women with hereditary ovarian cancer mutations provide many insights into the early events of carcinogenesis and process of malignant transformation. Here we review cancer pathogenesis in hereditary cases of ovarian cancer, the occurrence of pre-invasive lesions and occult carcinoma in mutation carriers and their clinical management.
- Published
- 2022
- Full Text
- View/download PDF
46. An Assessment of Ovarian Cancer Histotypes Across the African Diaspora.
- Author
-
George SHL, Omotoso A, Pinto A, Mustapha A, Sanchez-Covarrubias AP, Umar UA, Umar AB, Oluwasola TA, Okolo CA, Anthony UU, Ukekwe FI, Bakari MA, Dahiru AMC, Abdullahi HI, Abimiku BA, Abdurrahman A, Usman A, Ahmed SA, Usman HA, Kabir A, Eleje GU, Chiemeka ME, Nzeribe E, Nweke I, Kadas S, Suleiman DE, Ekanem E, Uche UM, Paul J, Agwu UM, Edegbe FO, Anorlu RI, Banjo A, Ajenifuja KO, Fawole AA, Kazeem IOO, Magaji F, Silas O, Athanasius BP, Tamunomie NK, Bassey E, Abudu K, Ango IG, Abdullahi K, Lawal I, Kabir SA, Ekanem V, Ezeanochie M, Yahaya UR, Castillo MN, Bahall V, Chatrani V, Brambury I, Bowe S, Halliday D, Bruney G, Butler R, Ragin C, Odedina F, Chamala S, Schlumbrecht M, and Audu B
- Abstract
Objective: Ovarian cancer in Black women is common in many West African countries but is relatively rare in North America. Black women have worse survival outcomes when compared to White women. Ovarian cancer histotype, diagnosis, and age at presentation are known prognostic factors for outcome. We sought to conduct a preliminary comparative assessment of these factors across the African diaspora., Methods: Patients diagnosed with ovarian cancer (all histologies) between June 2016-December 2019 in Departments of Pathology at 25 participating sites in Nigeria were identified. Comparative population-based data, inclusive of Caribbean-born Blacks (CBB) and US-born Blacks (USB), were additionally captured from the International Agency for Research on Cancer and Florida Cancer Data Systems. Histology, country of birth, and age at diagnosis data were collected and evaluated across the three subgroups: USB, CBB and Nigerians. Statistical analyses were done using chi-square and student's t-test with significance set at p<0.05., Results: Nigerians had the highest proportion of germ cell tumor (GCT, 11.5%) and sex-cord stromal (SCST, 16.2%) ovarian cancers relative to CBB and USB (p=0.001). CBB (79.4%) and USB (77.3%) women were diagnosed with a larger proportion of serous ovarian cancer than Nigerians (60.4%) (p<0.0001). Nigerians were diagnosed with epithelial ovarian cancers at the youngest age (51.7± 12.8 years) relative to USB (58.9 ± 15.0) and CBB (59.0± 13.0,p<0.001). Black women [CBB (25.2 ± 15.0), Nigerians (29.5 ± 15.1), and USB (33.9 ± 17.9)] were diagnosed with GCT younger than White women (35.4 ± 20.5, p=0.011). Black women [Nigerians (47.5 ± 15.9), USB (50.9 ± 18.3) and CBB (50.9 ± 18.3)] were also diagnosed with SCST younger than White women (55.6 ± 16.5, p<0.01)., Conclusion: There is significant variation in age of diagnosis and distribution of ovarian cancer histotype/diagnosis across the African diaspora. The etiology of these findings requires further investigation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 George, Omotoso, Pinto, Mustapha, Sanchez-Covarrubias, Umar, Umar, Oluwasola, Okolo, Anthony, Ukekwe, Bakari, Dahiru, Abdullahi, Abimiku, Abdurrahman, Usman, Ahmed, Usman, Kabir, Eleje, Chiemeka, Nzeribe, Nweke, Kadas, Suleiman, Ekanem, Uche, Paul, Agwu, Edegbe, Anorlu, Banjo, Ajenifuja, Fawole, Kazeem, Magaji, Silas, Athanasius, Tamunomie, Bassey, Abudu, Ango, Abdullahi, Lawal, Kabir, Ekanem, Ezeanochie, Yahaya, Castillo, Bahall, Chatrani, Brambury, Bowe, Halliday, Bruney, Butler, Ragin, Odedina, Chamala, Schlumbrecht and Audu.)
- Published
- 2021
- Full Text
- View/download PDF
47. Factors Predicting Type II Histology in Endometrial Biopsies Among Postmenopausal Minority Women at a Safety-Net Hospital.
- Author
-
Timmons D, Fein L, McCarter K, Huang M, Carugno JA, Gelman J, Strong A, and Schlumbrecht M
- Subjects
- Aged, Biopsy, Haiti, Humans, Middle Aged, Retrospective Studies, Postmenopause, Safety-net Providers
- Abstract
Background: Rates of type II endometrial cancers (EC) are increasing in the United States, especially in minority women. The purpose of this project was to examine a primarily minority and low socioeconomic status patient population in a public hospital to identify risk factors associated with the finding of type II histology in endometrial biopsies (EMBs). Materials and Methods: A retrospective chart review was performed of patients who underwent an EMB between 2010 and 2016. Included patients were postmenopausal women older than 50 years with biopsy-proven EC. Basic demographic data were analyzed, along with indication for EMB and ultrasound findings. Statistics were completed using analysis of variance and logistic regression with significance set at p < 0.05. Results: Four hundred sixty-one EMB results were reviewed. Around 17.4% ( n = 80) resulted in a diagnosis of EC, with 45% ( n = 36) being type II histology. Average age was 62.5 (standard deviation [SD] = 7.63), and the majority (64%) were Hispanic. Type II malignancies were diagnosed in 17% of Caucasians, 41% of Hispanics, and 61% of blacks/Haitians ( p = 0.03). Factors associated with type II tumors in univariable models included older age (odds ratio [OR] 1.10 [confidence interval; CI 1.03-1.18], p = 0.007), black/Haitian (vs. Caucasian) race (OR 8.75 [CI 0.86-88.70], p = 0.066), obesity (OR 0.39 [0.15-0.98], p = 0.044), and number of years since menopause (OR 1.06 [CI 1.01-1.12], p = 0.027), although none remained independently predictive in the multivariable analysis. Conclusion: This minority population of postmenopausal women with EC had a greater prevalence of type II histologies. Understanding this pattern may be helpful in expediting the workup for abnormal symptoms in these women and prompt a higher level of suspicion for EC.
- Published
- 2021
- Full Text
- View/download PDF
48. Racial/Ethnic Disparities in the Incidence of Epithelial Ovarian Cancer in Florida by Histology, 2001-2015: Analysis of Trends.
- Author
-
Westrick A, Schlumbrecht M, Pinheiro P, Hlaing W, Kobetz E, Feaster D, and Balise R
- Subjects
- Adult, Carcinoma, Ovarian Epithelial epidemiology, Female, Florida epidemiology, Florida ethnology, Humans, Incidence, Middle Aged, Racial Groups ethnology, Carcinoma, Ovarian Epithelial ethnology, Carcinoma, Ovarian Epithelial pathology, Health Status Disparities, Racial Groups statistics & numerical data
- Abstract
Objectives: Because the population in Florida is 25.6% Hispanic, it is possible to evaluate the influence of race and ethnicity within clinically relevant subgroups of women with epithelial ovarian cancer (EOC), including histology and tumor grade. This study explores racial/ethnic disparities in the incidence of EOC in Florida by histology and tumor grade., Methods: This study is an analysis of the Florida Cancer Database System. All incidence EOC cases from 2001 through 2015 were identified. Age-adjusted incidences were calculated and trends modeled by race/ethnicity and histology using Joinpoint and Poisson regression., Results: In total, 80% of the 21,731 women with EOC were White, followed by Hispanic (13.1%) and non-Hispanic Black (7.9%). All races/ethnicities had statistically significant declines in incidence, with non-Hispanic White and non-Hispanic Black women having the steepest declines (annual percentage change -2.5, 95% confidence interval [CI] -5.9 to -2.1 and annual percentage change -2.8, 95% CI -4.8 to -1.5, respectively). A decreased incidence trend across the time period was seen for all subgroups (relative risk 0.97 [95% CI 0.96-0.98], 0.96 [95% CI 0.96-0.99], and 0.98 [95% CI 0.96-0.99] for non-Hispanic White, non-Hispanic Black, and Hispanic). High-grade EOC incidence for all groups did not change with time., Conclusions: We found significant declines in the incidence of EOC for all races/ethnicities, but not for high-grade EOC. The observed incidence decline in Hispanic women differs from previous research. More research is needed to understand women the causes of overall racial/ethnic differences and the decline in EOC.
- Published
- 2021
- Full Text
- View/download PDF
49. Human Papilloma Virus Distribution Across the African Diaspora.
- Author
-
Jeudin P, Abebe T, Butler R, Hooi D, Watt A, Capo-Chichi CD, George S, Ragin C, McFarlane Anderson N, and Schlumbrecht M
- Subjects
- Bahamas, Benin, Curacao, Ethiopia, Female, Genotype, Human Migration, Humans, Jamaica, Papillomaviridae genetics, Trinidad and Tobago, Alphapapillomavirus, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Uterine Cervical Neoplasms
- Abstract
Purpose: Understanding the distribution of human papilloma virus (HPV) subtypes in limited-resource settings is imperative for cancer prevention strategies in these regions. The objective of our study is to compare the prevalence of cervical HPV genotypes in women across the African diaspora., Methods: This study was approved by the African Caribbean Consortium (AC3). Six member institutions (Benin, Ethiopia, The Bahamas, Tobago, Curacao, and Jamaica) provided independently collected HPV data. Prevalence comparisons across for each nation were performed followed by an assessment of anticipated 9-valent vaccine coverage. Chi-square or Fisher's exact tests were used with significance at P < .05., Results: One thousand three hundred fifty high-risk (HR) and 584 low-risk (LR) HPV subtypes were identified in the entire cohort. The most common HR HPV subtype was HPV 16 (17.9%) of infections. The distribution of HR and LR subtypes varied by country. The proportion of HR-HPV subtypes covered by the current 9-valent vaccine was lower in African countries compared with the Caribbean countries (47.9% v 67.9%; P < .01). No significant difference was seen for LR subtypes (8.1% African continent v 5.2% Caribbean; P = .20). Marked variation in the proportion of infections covered by the 9-valent vaccine persisted in individual countries., Conclusion: Significant variations in HPV prevalence were identified among African and Afro-Caribbean women. A large number of women in these regions are potentially uncovered by current vaccination formulation, particularly low-risk HPV infections., Competing Interests: Matthew SchlumbrechtConsulting or Advisory Role: TesaroNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF
50. Lost opportunities for mismatch repair (MMR) screening among minority women with endometrial cancer.
- Author
-
Huang M, Hunter T, Fein LA, Galli J, George S, Schlumbrecht M, McCarter K, Sinno AK, Guido LP, and Pinto A
- Subjects
- Adult, Aged, Biomarkers, Tumor, Early Detection of Cancer, Endometrial Neoplasms diagnosis, Female, Genetic Counseling, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Mass Screening, Middle Aged, DNA Mismatch Repair, Endometrial Neoplasms epidemiology, Endometrial Neoplasms etiology, Minority Groups statistics & numerical data
- Abstract
Lynch Syndrome (LS) prevalence in underrepresented minorities are lacking. The objective of this study was to assess the prevalence of LS in a minority patient population. Secondary objectives included identifying factors associated with successful LS screening and to characterize clinicopathologic features. Women with endometrial cancer treated within a university system from 2014 and 2016 were included. Immunohistochemistry (IHC) results of MLH1, PMS2, MSH2 and MSH6 were obtained from medical records and clinicopathologic factors abstracted. Patients not previously screened for LS were screened. 276 patients were evaluable. More minority women were screened as part of their routine cancer care (p = 0.005). Additionally, women 50 years or younger were more likely to be screened for LS compared to women older than 51(p = 0.009) and uninsured or reliant on Medicaid patients (p = 0.011) were more likely to be screened during routine care. Six patients received confirmatory germline testing for LS (4.3%), and another 8 patients had a staining pattern suggestive of LS. In an underrepresented population, the rate of LS in endometrial cancer is similar to previous reports. LS may be under diagnosed and opportunities missed when universal screening is not applied in minority women.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.